Kanvas Biosciences
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
$48MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
Provides technology platform for designing employer-sponsored health insurance
Develops a ureteroscopic system for complete kidney stone clearance